Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vonoprazan + amoxicillin + bifidobacterium tetravaccae
- Development stage
- Unknown
- Lead developer
- Phathom Pharmaceuticals
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics, Small Molecules
- Administration
- Oral
01
Overview
Vonoprazan + amoxicillin + bifidobacterium tetravaccae is an investigational combination regimen being evaluated in a Phase 4, open-label, randomized controlled trial (NCT07306988) for the treatment of Helicobacter pylori infection and associated metabolic syndrome. The regimen consists of vonoprazan (a potassium-competitive acid blocker), amoxicillin (a beta-lactam antibiotic), and Bifidobacterium tetravaccae (also referred to as Bifidobacterium tetravaccine or Bifidobacterium tetragenous, a quadruple probiotic tablet containing Bifidobacterium infantis, Lactobacillus acidophilus, Enterococcus faecalis, and Bacillus cereus). This probiotic-augmented dual therapy is designed to eradicate H. pylori while mitigating gut microbiota dysbiosis and improving metabolic syndrome-related parameters such as blood glucose and lipid profiles.
- Other names
- vonoprazan + amoxicillin + bifidobacterium tetravaccinevonoprazan + amoxicillin + bifidobacterium tetragenousvonoprazan + amoxicillin + bifidobacterium tetragenous viable bacteria
02
Targets
ATP4A (Potassium–transporting ATPase alpha chain 1)PBP (Penicillin-binding protein family)
Beyond the preview
Go deeper on vonoprazan + amoxicillin + bifidobacterium tetravaccae.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vonoprazan + amoxicillin + bifidobacterium tetravaccae.